Amgen

5-Star Stocks Poised to Pop: PDL BioPharma Fri, 12/17/2010 - 11:05 by Brian D. Pacampara Based on the aggregated intelligence of 170,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotechnology company PDL BioPharma(Nasdaq: PDLI) has earned a coveted five-star ranking. Comments Read more	How Cheap Is Amgen's Stock by the Numbers? Sun, 12/05/2010 - 00:34 by Anand Chokkavelu Numbers can lie -- yet they're the best first step in determining whether a stock is a buy. In this series, we use some carefully chosen metrics to size up a stock's true value based on the following clues: Comments Read more	RNAi Is On Sale Wed, 12/01/2010 - 11:27 by Brian Orelli After bashing RNAi over the past few years -- see here and here for examples -- I think the pioneering technology is looking a little more appetizing. The field has advanced, but more importantly, the prices have come down. A lot. Comments Read more
How Are the Margins at Biogen Idec? Wed, 11/03/2010 - 09:57 by Seth Jayson Margins matter. The more Biogen Idec (Nasdaq: BIIB) keeps of each buck it earns in revenue, the more money it has to invest in growth, fund new strategic plans, or (gasp!) distribute to shareholders. Healthy margins often separate pretenders from the best stocks in the market. That's why I check on my holdings' margins at least once a quarter. I'm looking for the absolute numbers, comparisons to sector peers and competitors, and any trend that may tell me how strong Biogen Idec's competitive position could be. Comments Read more	Time to Sell Amgen? Wed, 11/03/2010 - 09:55 by Jeremy Phillips Should you sell Amgen (Nasdaq: AMGN) today? Comments Read more	Companion Diagnostics in Cancer Drug Development Thu, 10/28/2010 - 10:36 by Ralph Casale Over the past two days, I've been commenting on Boston's War on Cancer, the biotechnology forum organized by Xconomy. The event consisted of a few company presentations and also some organized discussion sections. As is the purpose for attending these occasions, the forum has had me considering and reconsidering some aspects of oncology research, pharmaceutical operations, and of course, attractive investments in and surrounding these enterprises. Comments Read more
The State of Oncology and the Future for Biotech Investors Tue, 10/26/2010 - 12:20 by Ralph Casale On Oct. 20, media organization and Fool content partnerXconomy organized a forum on oncology research and therapeutic development termed "Boston's War on Cancer." The event was hosted by Millennium: The Takeda Oncology Company. Millennium CEO Dr. Deborah Dunsire provided the opening on the state of the industry. Comments Read more	Can You Trust This Cash Flow? Sat, 10/23/2010 - 10:39 by Seth Jayson Although business headlines still tout earnings numbers, many investors have moved past net earnings as a measure of a company's economic output. That's because earnings are very often less trustworthy than cash flow, since earnings are more open to manipulation based on dubious judgment calls. Comments Read more	When the Status Quo Is a Big Win Wed, 10/20/2010 - 12:13 by Brian Orelli Hear that? It's silence. No buzzer of rejection. Comments Read more
How Well Do You Use Cash, Amgen? Tue, 08/24/2010 - 12:42 by Jim Mueller There are two parts to successful investing: finding the winners and avoiding the losers. Comments Read more	On the Path to a Blockbuster Sat, 07/31/2010 - 00:30 by Brian Orelli Prolia might be able to save Amgen (Nasdaq: AMGN). But not yet. More in a moment. Comments Read more	Amgen's anti-osteoporosis drug, Prolia wins FDA approval Wed, 06/02/2010 - 17:48 by Neka Sehgal Amgen received approval from the U.S. Food and Drug Administration (FDA) for marketing the drug, Prolia, it has developed to treat and prevent bone loss in postmenopausal women who are at increased risk of fractures. Comments Read more